Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Consequences of Flutemetamol-PET-scanning
NCT02353949Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- May 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of flutemetamol in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Dementia, sponsored by University of Zurich. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 at 3 months. Started May 2015; status: terminated.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on NCT02353949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353949.